Blog
Tigatuzumab Biosimilar: Harnessing DR5 for Targeted Cancer Therapy
Tigatuzumab is a monoclonal antibody targeting death receptor 5 (DR5), a member of the tumor necrosis factor receptor (TNFR) superfamily. By activating DR5, Tigatuzumab induces apoptosis
…
17th Dec 2025
Enavatuzumab Biosimilar: Advancing TWEAKR-Targeted Therapy in Cancer
Enavatuzumab is a monoclonal antibody targeting TWEAK receptor (TWEAKR, also known as Fn14), a member of the tumor necrosis factor receptor (TNFR) family. Overexpressed in many solid tumo
…
17th Dec 2025
Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars
Unlocking the Potential of Pembrolizumab in ResearchIs Pembrolizumab Safe?Pembrolizumab is widely recognized as safe for most patients, with side effects ranging from mild to severe. Com
…
28th Dec 2024
Vorsetuzumab: Advancing Cancer Research with CD70 Targeting
Vorsetuzumab, a monoclonal antibody targeting CD70, is an investigational therapy designed to treat hematologic malignancies and solid tumors. CD70, a member of the tumor necrosis factor
…
28th Dec 2024
Daratumumab: Advancing Research in Multiple Myeloma and Beyond
Daratumumab, a human monoclonal antibody targeting CD38, is a breakthrough therapy for multiple myeloma (MM) and other CD38-expressing hematologic malignancies. It enhances immune-mediate
…
28th Dec 2024
Talacotuzumab: Exploring CD123-Targeting Therapies in AML and MDS Research
Talacotuzumab, a humanized monoclonal antibody targeting CD123, has shown promise in treating acute myeloid leukemia (AML) and other hematologic malignancies. As a key immunotherapy, it e
…
28th Dec 2024
Magrolimab: Unveiling the Role of Anti-CD47 in Cancer Research and Beyond
What You Need to Know About MagrolimabWhat is Magrolimab?Magrolimab is an anti-CD47 monoclonal antibody that targets the "don't eat me" signal on cancer cells, promoting their destructio
…
28th Dec 2024
Rituximab Biosimilar: Transforming CD20-Targeted Therapy for Hematologic Malignancies
Rituximab is a monoclonal antibody targeting CD20, a cell surface protein found on B lymphocytes. By engaging immune-mediated mechanisms, Rituximab eliminates CD20-positive B cells, makin
…
12th Dec 2024
Tiragolumab Biosimilar: Enhancing Immune Checkpoint Therapy with TIGIT Inhibition
Tiragolumab is a monoclonal antibody targeting TIGIT (T-cell immunoglobulin and ITIM domain), an immune checkpoint receptor that suppresses T-cell and natural killer (NK) cell activity in
…
12th Dec 2024
Vibostolimab Biosimilar: Advancing Immune Activation with TIGIT Inhibition
Vibostolimab is a monoclonal antibody that targets TIGIT (T-cell immunoglobulin and ITIM domain), an immune checkpoint receptor that suppresses T-cell and natural killer (NK) cell activit
…
12th Dec 2024
Pinatuzumab Biosimilar: Advancing CD22-Targeted Therapy in B-Cell Malignancies
Pinatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD22, a cell surface marker highly expressed on malignant B cells. It delivers a potent cytotoxic agent directly to CD22-
…
12th Dec 2024
Girentuximab Biosimilar: Targeting Carbonic Anhydrase IX (CAIX) for Cancer Therapy
Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), a tumor-associated antigen overexpressed in clear cell renal cell carcinoma (ccRCC) and hypoxic tumors. By se
…
10th Dec 2024
Tesnatilimab Biosimilar: Advancing CD38-Targeted Therapy
Tesnatilimab is a monoclonal antibody targeting CD38, a transmembrane glycoprotein highly expressed on malignant plasma cells in multiple myeloma (MM) and other hematologic malignancies.
…
10th Dec 2024
Sacituzumab Biosimilar: Advancing Trop-2-Targeted Cancer Therapy
Sacituzumab govitecan is an innovative antibody-drug conjugate (ADC) targeting Trop-2, a transmembrane glycoprotein overexpressed in many epithelial cancers. By selectively delivering a c
…
10th Dec 2024
Ipilimumab Biosimilar: Expanding Access to CTLA-4 Inhibition
Ipilimumab (Yervoy) is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a key immune checkpoint receptor. By inhibiting CTLA-4, Ipilimumab enhances T-
…
9th Dec 2024
Amatuximab Biosimilar: Advancing Mesothelin-Targeted Therapy for Cancer
Amatuximab is a monoclonal antibody targeting mesothelin, a tumor-associated antigen overexpressed in several aggressive cancers, including mesothelioma and pancreatic cancer. By binding
…
8th Dec 2024
Iscalimab Biosimilar: Advancing CD40-Targeted Therapy for Immune Modulation
Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key receptor in the immune system. By blocking CD40-CD40L interactions, Iscalimab inhibits immune activation, making it a pro
…
7th Dec 2024
Ifabotuzumab Biosimilar: Advancing EGFRvIII-Targeted Cancer Therapy
Ifabotuzumab is a monoclonal antibody targeting the EGFRvIII mutation, a tumor-specific variant of the epidermal growth factor receptor (EGFR). This mutation is associated with aggressive
…
7th Dec 2024
Varlilumab Biosimilar: Enhancing Immune Activation via CD27-Targeted Therapy
Varlilumab is a monoclonal antibody targeting CD27, a critical costimulatory receptor in the immune system. Acting as a CD27 agonist, Varlilumab enhances T-cell activation and effector fu
…
5th Dec 2024
Brentuximab Biosimilar: Advancing CD30-Targeted Therapy
Brentuximab vedotin is a CD30-targeting antibody-drug conjugate (ADC) approved for treating CD30-positive malignancies, such as Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (A
…
5th Dec 2024
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies
1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive c
…
5th Dec 2024
Gemtuzumab Biosimilar: Advancing CD33-Targeted Therapy for AML
Gemtuzumab ozogamicin is a CD33-targeting antibody-drug conjugate (ADC) approved for the treatment of acute myeloid leukemia (AML). By selectively delivering a cytotoxic payload to CD33-p
…
5th Dec 2024
Indatuximab Biosimilar: A New Frontier in CD138-Targeted Cancer Therapy
Indatuximab ravtansine is a CD138-targeting antibody-drug conjugate (ADC) designed for the treatment of multiple myeloma and other CD138-expressing cancers. By delivering a cytotoxic payl
…
4th Dec 2024
Vopratelimab Biosimilar: A Next-Generation ICOS Agonist for Cancer Immunotherapy
Vopratelimab is a monoclonal antibody targeting inducible T-cell costimulator (ICOS), a key receptor involved in T-cell activation and immune regulation. By selectively activating ICOS, V
…
4th Dec 2024